← Leaderboards
Sarah Elizabeth Palmer
Karolinska Institute
$3,284,571
Attributed
$3,284,571
Total exposure
6
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $472K · FY2010–25$500K$375K$250K$125K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,284,571 · 6
By mechanism
U19$1,859,868 · 1
R21$1,174,452 · 4
R56$250,251 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Antiretroviral Therapy”
- James Dennis Neaton · Northwestern University$279,044,427
- Lawrence Corey · Fred Hutchinson Cancer Center$278,220,635
- Constance Ann Benson · University Of California, San Diego$241,336,455
- Carol Nesel · Westat$188,148,170
- Judith S. Currier · University Of California Los Angeles$182,467,520
- Barbara Driver · Westat, Inc.$170,789,549
Research focus
Antiretroviral TherapyCellsViralVirusCd4 Positive T LymphocytesViremiaPlasmaInfectionHiv InfectionsMemory Cd4 T LymphocyteGeneticViral Load ResultGenetic TranscriptionPeripheral BloodT Memory CellSamplingRestSourceCell TypeGut Associated Lymphoid TissueMemoryImmuneRna SequencesEffective Therapy
Grant awards (14)
Delineating the viro-immunological factors contributing to transient HIV control during consecutive analytical treatment interruptions$174,318
R21 · FY2025 · AI · contact PI
Delineating the viro-immunological factors contributing to transient HIV control during consecutive analytical treatment interruptions$110,414
R21 · FY2024 · AI · contact PI
Combining immunogenic peptides and Nef blockade to enhance CD8 T-cell-mediated clearance of HIV-infected cells$160,878
R21 · FY2023 · AI · contact PI
Combining immunogenic peptides and Nef blockade to enhance CD8 T-cell-mediated clearance of HIV-infected cells$136,122
R21 · FY2022 · AI · contact PI
Genetic characterization of the HIV-1 reservoir after Vacc-4x and romidepsin therapy$139,120
R21 · FY2019 · AI · contact PI
Genetic characterization of the HIV-1 reservoir after Vacc-4x and romidepsin therapy$156,600
R21 · FY2018 · AI · contact PI
Viral reservoirs and sanctuaries in HAART - treated patients: role and mechanisms$279,351
U19 · FY2015 · AI · contact PI
Genetic analysis of unspliced HIV RNA produced during HDAC inhibitor therapy$140,400
R21 · FY2015 · AI · contact PI
Viral reservoirs and sanctuaries in HAART - treated patients: role and mechanisms$315,412
U19 · FY2014 · AI · contact PI
Genetic analysis of unspliced HIV RNA produced during HDAC inhibitor therapy$156,600
R21 · FY2014 · AI · contact PI
Viral reservoirs and sanctuaries in HAART - treated patients: role and mechanisms$408,861
U19 · FY2013 · AI · contact PI
Viral reservoirs and sanctuaries in HAART - treated patients: role and mechanisms$404,949
U19 · FY2012 · AI · contact PI
Viral reservoirs and sanctuaries in HAART - treated patients: role and mechanisms$451,295
U19 · FY2011 · AI · contact PI
Targeting_the_Source_of_Persistent_HIV_Viremia$250,251
R56 · FY2010 · AI · contact PI